Aerie’s glaucoma drug Rhopressa wins backing from U.S. FDA panel

Share this post

(Reuters) – The benefit of Aerie Pharmaceuticals Inc’s experimental glaucoma treatment outweighs the risks and the drug should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Friday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply